heartflow Data Shows Plaque Volume Predicts Heart Attack and Death Risk
NEW ORLEANS, Nov. 09, 2025 – Heartflow, Inc. (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), announced significant findings from the FISH&CHIPS Study at the American Heart Association (AHA) Scientific Sessions 2025. This data reinforces the value of AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging as a tool for proactive CAD care.
The retrospective analysis examined nearly 8,000 symptomatic patients from the FISH&CHIPS Study, making it the largest validation to date of the Heartflow Plaque Staging framework, which uses total plaque volume (TPV) measurement.1
Key findings demonstrate a clear link between plaque burden and future cardiac events:
- Patients with the highest TPV stage had over a 5x greater risk of major cardiovascular events compared to those with the lowest stage (hazard ratio 5.10, p-value < 0.0001).
- Higher plaque volume stages were independently linked to significantly increased rates of cardiovascular death and myocardial infarction over a median 3.3 years of follow-up.
- These associations remained significant even after accounting for coronary stenosis, FFRCT values, and traditional cardiovascular risk factors.
“This study strongly validates TPV-based staging, measured with Heartflow Plaque Analysis, as a predictor of future heart attacks or cardiovascular death,” stated Timothy Fairbairn, Ph.D., principal investigator for the FISH&CHIPS study at Liverpool Heart and Chest Hospital and Associate Professor at the University of Liverpool, UK.”Accurately measuring plaque allows cardiologists to better identify high-risk patients beyond standard risk factors, enabling personalized treatment to prevent future cardiac events.”
These findings complement results from the DECIDE Registry presented at the Society of Cardiovascular Computed Tomography (SCCT) 2025 annual Scientific Meeting,further solidifying the clinical benefits of Heartflow’s technology.
1Data on file, Heartflow, Inc.